Truist Financial
MDGL icon

Truist Financial’s Madrigal Pharmaceuticals MDGL Stock Holding History

Truist Financial’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$287K Sell
534
-15
-3% -$7.68K ﹤0.01% 2571
2026
Q1 		$287K Sell
549
-20
-4% -$9.55K ﹤0.01% 2416
2025
Q4 		$331K Sell
569
-34
-6% -$17.4K ﹤0.01% 2269
2025
Q3 		$277K Buy
+603
New +$225K ﹤0.01% 2371
2024
Q3 		– Sell
-772
Closed -$216K – 2633
2024
Q2 		$216K Buy
+772
New +$184K ﹤0.01% 2462

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Truist Financial's MDGL Position: Q2 2026 in Review

Truist Financial reduced its Madrigal Pharmaceuticals (MDGL) stake by 2.7% in Q2 2026, selling an estimated $7.68K and leaving 534 shares worth $287K. The position accounts for ﹤0.01% of the portfolio, ranked #2571.

Truist Financial first reported a position in MDGL in Q2 2024 and has held it in 5 quarters since. The position peaked at $331K in Q4 2025. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Truist Financial held 534 shares of Madrigal Pharmaceuticals worth $287K as of Q2 2026.
  • Truist Financial sold 15 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $7.68K.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Truist Financial's portfolio in Q2 2026, its #2571 holding.
  • Truist Financial first reported a position in Madrigal Pharmaceuticals in Q2 2024 and has held it in 5 quarters since.
  • Truist Financial's Madrigal Pharmaceuticals position peaked at $331K in Q4 2025.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Truist Financial's 13F filing for Q2 2026, filed 28 Jul 2026.